Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Relay Therapeutics designs small molecule drugs that target proteins previously thought impossible to drug, aiming to treat cancer and genetic diseases.
Relay Therapeutics is a drug discovery company that goes after a stubborn problem in medicine: many proteins in the body that cause disease have smooth, featureless surfaces with no obvious pocket for a drug to grab onto. Most pills work like keys sliding into a lock, but these proteins offer no lock. Relay's bet is that proteins are not actually rigid — they wiggle and shift shape, and if you can catch one in a rare, fleeting pose, you can build a drug that sticks.
To find those hidden poses, Relay leans heavily on computers. It combines powerful molecular simulations, machine learning, and real laboratory experiments, mixing them in a loop so each informs the other. The idea is to shrink the years of trial and error that traditionally go into finding a new medicine. Relay focuses on small molecule pills — cheap to make and easy for patients to take — in two main areas: cancer and genetic diseases. The company's lead program targets a specific cancer mutation, with a drug candidate in clinical testing that it believes could work across multiple tumor types. Relay also has programs aimed at genetic diseases and other cancer targets at earlier stages. Like most clinical-stage biotech firms, it earns no product revenue yet; it stays alive on cash raised from investors, plus partnerships where larger drugmakers pay it upfront and promise later payments if programs succeed.
That makes Relay a high-risk, high-reward story: every dollar goes into research, and the payoff hangs on whether its molecules prove safe and effective in human trials. Failures in biotech are common and brutal, and success is rare — but a single approved drug that hits a previously undruggable target could change both patients' lives and the company's fortunes.
Saved answer · last researched 15 Nov 2026